Full-Time

Senior Director Program & Portfolio Management

Program & Portfolio Management

Vera Therapeutics

Vera Therapeutics

201-500 employees

Develops therapies for immunologic diseases

Compensation Overview

$230k - $300k/yr

+ Annual Bonus + New Hire Equity + Performance-based Equity

Daly City, CA, USA

In Person

On-site presence near Brisbane, California or Boston, Massachusetts.

Bachelor's, MBA, PhD, MD

Category
Business & Strategy (1)
Required Skills
Visio
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Vera Therapeutics

See people who can refer or advise you

Requirements
  • BA/BS degree with 15+ years of biotechnology or pharmaceutical industry experience required; advanced degree (PhD, MD, MBA) preferred
  • Deep, hands-on experience managing late-stage development programs through registration and approval; direct BLA/NDA experience preferred
  • A blend of large biopharma and smaller, fast-moving biotech experience strongly preferred, combined with a high level of professionalism and experience working with executive leadership teams
  • Demonstrated experience leading cross-functional development sub-teams and running formal governance bodies at the program or portfolio level
  • Demonstrated people management skills, specifically managing program or project managers, required
  • Exceptional stakeholder management skills, with a proven ability to build trust and drive alignment with executive leaders and senior functional heads
  • Rigorous command of standard program management deliverables and disciplines, including integrated project plans, timelines, dashboards, and RAID logs
  • Excellent meeting management skills, including agenda design, facilitation, and producing clear, accurate, professional minutes and follow-up
  • Proven ability to operate as an execution owner, translating strategic direction set by others into a well-managed, on-track operating plan
  • High level of accuracy, attention to detail, and follow-through; comfortable managing significant offline stakeholder coordination between formal meetings
  • Ability to communicate effectively and with executive presence across the organization at all levels
  • Proven ability to manage competing priorities, timelines, and stakeholders in a fast-paced, rapid-growth environment
  • Experience with Smartsheet or similar project management tools preferred
  • PMP or equivalent certification a plus
  • Proficient in Microsoft Office, including Word, Excel, PowerPoint, Project, Visio, or other timeline tools
Responsibilities
  • Own the integrated Trutakna (atacicept-vymj) project plan and the full suite of supporting program management deliverables, timelines, milestones, dependencies, critical path, dashboards, and RAID logs, ensuring accuracy and decision-readiness at all times
  • Lead the Development Sub-Team, driving successful cross-functional execution of Trutakna development programs across Clinical Development, Regulatory Affairs, CMC, Biostatistics, Drug Safety, and other R&D functions
  • Lead Research and Development Governance, overseeing agenda development, meeting facilitation, decision tracking, and resolution of action items
  • Manage the weekly Development Sub-Team meeting end to end: build the agenda, produce meeting presentations, capture and distribute clear minutes, and drive closure on open items between meetings
  • Serve as a champion of PMO resources to direct reports and the broader organization. Lead with Program Management best practices, bringing rigor and discipline to teams and the PPM function.
  • Serve as the principal execution partner to the Global Program Team Lead (GPTL) and GPT Program Manager, translating GPT-level strategy into coordinated execution plans and ensuring program risk and status are communicated clearly across governance layers
  • Partner closely with the Chief Medical Officer, Executive Vice President, Clinical Development and the Executive Vice President, Development Operations to keep clinical execution, timelines, and risk visibility tightly aligned with program governance and the RDRC
  • Manage and mentor a team of direct report program and/or project managers supporting R&D, fostering professional development and building program management capability across the team
  • Proactively identify and manage program risks and issues in partnership with functional leaders, escalating with clear options and recommendations when executive decisions are required
  • Maintain continuous, high-touch engagement with cross-functional stakeholders between formal governance touchpoints, ensuring alignment and swift resolution of emerging issues
  • Act as a trusted, credible partner to functional leaders and executive stakeholders, communicating program status, risks, and dependencies with clarity, precision, and professionalism
  • Continuously strengthen program management rigor and discipline within R&D, including governance cadence, reporting tools, and cross-functional communication norms
  • May support other programs or R&D initiatives as needed
Desired Qualifications
  • Experience with Smartsheet or similar project management tools preferred
  • PMP or equivalent certification a plus

Vera Therapeutics is a clinical-stage biotechnology company developing therapies for immunological diseases, with a focus on IgA nephropathy and BK virus management. Its lead asset, MAU868, is a neutralizing antibody that targets BK virus and is developed under an exclusive worldwide license from Pfizer. The company differentiates itself through the Pfizer license and a strategy that emphasizes licensing and commercialization to bring therapies to immunocompromised patients, especially those undergoing organ or stem cell transplants. The goal is to improve outcomes for patients with immunologic and rare diseases by translating research into accessible treatments and building a high-performance organization.

Company Size

201-500

Company Stage

IPO

Headquarters

Brisbane, California

Founded

2016

Get referred to Vera Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval on July 7, 2026 opens immediate U.S. revenue and launch execution.
  • ORIGIN 3 eGFR results arrive in Q3 2026, enabling full-approval filing.
  • Vera held $596.8 million cash and a $500 million Oxford facility in March 2026.

What critics are saying

  • Novartis won full IgAN approval July 17, 2026, stealing physician attention and formulary slots.
  • Vertex's povetacicept faces a November 30, 2026 PDUFA, compressing Vera's first-mover advantage.
  • ORIGIN 3 confirmatory data controls TRUTAKNA's future; failure triggers withdrawal and crushes the franchise.

What makes Vera Therapeutics unique

  • TRUTAKNA became the first FDA-approved dual BAFF/APRIL IgAN therapy on July 7, 2026.
  • Patients self-inject weekly at home, reducing infusion-center dependence and boosting convenience.
  • Vera controls atacicept, VT-109, and MAU868 worldwide, with Stanford-backed BAFF/APRIL science.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Profit Sharing

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Adoption Assistance

Childcare Support

Elder Care Support

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

2%

2 year growth

5%
Yahoo Finance
Jul 9th, 2026
Vera Therapeutics appoints Nancy Boman as chief regulatory officer, William Turner to retire

Vera Therapeutics has appointed Nancy Boman as Chief Regulatory Officer, replacing William Turner, who is retiring after helping secure accelerated approval for the company's first therapy, TRUTAKNA (atacicept-vymj), for IgA nephropathy. Turner will transition to a Strategic Advisor role in the third quarter. Boman brings over 25 years of regulatory affairs experience. She previously served as Chief Regulatory Officer at Kyverna Therapeutics, Adicet Bio, Encoded Therapeutics, and Novartis Gene Therapies. She also held leadership positions at Amgen, Genentech, and Alder. The Brisbane, California-based commercial-stage biotechnology company plans to pursue new indications for TRUTAKNA in other autoimmune kidney diseases whilst developing approval pathways for other molecules in its pipeline.

Associated Press
Jul 7th, 2026
FDA approves Vera's TRUTAKNA for IgA nephropathy, first BAFF and APRIL inhibitor

The US Food and Drug Administration has granted accelerated approval to Vera Therapeutics' TRUTAKNA for treating adult patients with primary IgA nephropathy at risk for disease progression. TRUTAKNA is the first therapy that binds both B-cell activating factor and A proliferation-inducing ligand, targeting immunological drivers of the disease. In the interim analysis of the ongoing ORIGIN 3 trial, participants achieved a 46% reduction from baseline in proteinuria, with a 42% reduction compared to placebo at 36 weeks. The therapy is administered as a 150 mg subcutaneous injection once weekly via an autoinjector at home. The accelerated approval is based on proteinuria reduction. Continued approval depends on verification of clinical benefit in the ongoing trial, with results expected in Q3 2026.

Associated Press
May 7th, 2026
Vera Therapeutics receives FDA priority review for IgAN drug, eyes July approval

Vera Therapeutics, a biotechnology company developing treatments for immunological diseases, reported a first-quarter net loss of $121 million, or $1.69 per share, compared to a $51.7 million loss in the same period last year. The FDA granted priority review to Vera's biologics licence application for atacicept, an investigational treatment for IgA Nephropathy in adults, with a target decision date of 7 July 2026. The company is preparing for a mid-2026 US commercial launch pending regulatory approval. Vera reported $596.8 million in cash, cash equivalents and marketable securities as of 31 March 2026, which it believes will fund operations beyond potential approval and commercial launch. The company anticipates initial results from its PIONEER Phase 2 trial in the second quarter of 2026.

American Press
May 4th, 2026
Vera Therapeutics to participate in the Bank of America Securities 2026 Health Care Conference.

Vera Therapeutics to participate in the Bank of America Securities 2026 Health Care Conference. GlobeNewswire | Vera Therapeutics Today at 4:30am PDT BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) - Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Wednesday, May 13, 2026 Time: 4:20 PM PDT Webcast: https://bofa.veracast.com/webcasts/bofa/healthcare2026/24Ty86.cfm A replay of the event will be available for 90 days and can be accessed by visiting the "Investor Calendar" section of the Vera Therapeutics website. About Vera Therapeutics Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics' lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com. Forward-looking Statements Statements contained in this press release regarding matters, events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera Therapeutics' plans, commitments, aspirations and goals related to its product candidates. Words such as "anticipate," "believe," "expect," "may," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics' business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Associated Press
Mar 27th, 2026
Vera Therapeutics grants stock options and RSUs to new Chief Legal Officer

Vera Therapeutics has granted inducement awards to Jane Wright-Mitchell, its new Chief Legal Officer, consisting of non-qualified stock options to purchase 56,850 shares and restricted stock units underlying 42,403 shares of Class A common stock. The Compensation Committee approved the awards on 23 March 2026 under the company's 2024 Inducement Plan. The stock options have an exercise price of $40.73 per share and will vest over four years, with 25% vesting after the first anniversary and the remainder vesting monthly over 36 months. The RSU award will vest 25% annually over four years starting 20 May 2026. Vera Therapeutics is a late clinical-stage biotechnology company developing treatments for immunological diseases, with atacicept as its lead product candidate targeting autoimmune diseases including IgAN and lupus nephritis.